BNO 5.26% 20.0¢ bionomics limited

Ann: Commencement of BNC210 Phase 2 Agitation Trial, page-35

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 593 Posts.
    lightbulb Created with Sketch. 24
    Nice one Roka. The number of subjects is pretty easy to calculate for a given statistical power when you set the beta you are after. BNO would have had plenty of advice on this and they have needed up with a reasonably small number (at 193). And the three measures that may reach significance of p < 0.05 are the ones where they are likely to get a measure across the entire study group (hence the 3 they chose). It is not unusual to load in other secondary objectives.

    The value driver from the primary objective, if there is a significant result, is that they can then justify a PhIIb, if BNO wants to do that, and launch into conversations with a bigger partner to fund a PhIII. And both can occur simultaneously. GLTA
 
watchlist Created with Sketch. Add BNO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.